Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 19/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ifetroban SCHEMBL362594 | 1.00 | TBXA2R (0.98) | TBXA2R | |
| Bms-180291 SCHEMBL28190408 | 1.00 | TBXA2R (0.98) | TBXA2R | |
| Bms-180291 SCHEMBL28137 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL29502980 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Ifetroban SCHEMBL30218601 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL28136 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Ifetroban SCHEMBL28135 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| Bms-180291 SCHEMBL9589119 | 0.99 | TBXA2R (1.00) | TBXA2R | |
| SCHEMBL8918573 | 0.98 | TBXA2R (1.00) | TBXA2R | |
| Ifetroban SCHEMBL16212975 | 0.98 | TBXA2R (0.98) | TBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1039 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| US-20250049764-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | CUMBERLAND PHARMACEUTICALS INC. | 2025-02-13 | — | — | US | claimed |
| US-12161632-B2 | Compositions and methods of treating cardiac fibrosis with ifetroban | CUMBERLAND PHARMACEUTICALS INC. (US) | 2024-12-10 | — | — | US | claimed |
| US-20230270726-A1 | Compositions and Methods of Treating Cardiac Fibrosis with Ifetroban | VANDERBILT UNIVERSITY | 2023-08-31 | — | — | US | claimed |
| EP-3454850-B1 | COMPOSITIONS AND METHODS OF TREATING MUSCULAR DYSTROPHY WITH THROMBOXANE-A2 RECEPTOR ANTAGONISTS | CUMBERLAND PHARMACEUTICALS INC (US) | 2023-06-21 | — | — | EP | claimed |
| US-20230129262-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 | OGLETREE MARTIN (US) | 2023-04-27 | — | — | US | claimed |
| EP-4125882-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS OF THROMBOXANE A2 RECEPTOR ANTAGONIST FOR THE TREATMENT OF COVID-19 | Ogletree, Martin (US) | 2023-02-08 | — | — | EP | claimed |
| US-11571412-B2 | Thromboxane receptor antagonists in AERD/asthma | CUMBERLAND PHARMACEUTICALS INC. (US) | 2023-02-07 | — | — | US | claimed |
| CN-115624549-A | Compositions and methods for treating muscular dystrophy using thromboxane-A2 receptor antagonists | 坎伯兰医药品股份有限公司 | 2023-01-20 | — | — | CN | claimed |
| CN-109152767-B | Compositions and methods for treating muscular dystrophy using thromboxane-A2 receptor antagonists | 坎伯兰医药品股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-1642415-A | Palatable oral suspensions and methods of making same | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | CN | claimed |
| EP-1482789-A2 | PALATABLE ORAL SUSPENSION AND METHOD | Bristol-Myers Squibb Company (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20030187019-A1 | Palatable oral suspension and method | TOYAMA CHEMICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | claimed |
| WO-2003077842-A2 | PALATABLE ORAL SUSPENSION AND METHOD | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-25 | — | — | WO | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-5506248-A | SALT OF IFETROBAN AND ONE OR MORE BASIFYING AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-09 | — | — | US | claimed |
| CN-1118254-A | Pharmaceutical compositions having good dissolution properties | BRISTOL MYERS SQIBB COMPANY (US) | 1996-03-13 | — | — | CN | claimed |
| EP-0638310-A1 | Pharmaceutical compositions containing ifetroban | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-02-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187019-A1 | Palatable oral suspension and method | TAS2R20, TAS2R60, TAS2R30 | TBXA2R 1345/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | TBXA2R 162/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | TBXA2R 2982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.